THX Pharma Announces Cash Position as of December 31, 2025
THX Pharma, a biopharmaceutical company specializing in rare neurological diseases, has disclosed its cash position as of December 31, 2025. This announcement comes in the context of a strategic partnership with Biocodex announced in February 2026.
As of December 31, 2025, THX Pharma had a cash reserve of €7.764 million. In line with the agreement reached with Biocodex on February 10, 2026, the company will receive an initial payment of €12 million in March 2026. This contribution, added to the available cash at the end of December 2025 and an advance on funding for the Batten-1 program, results in a pro forma cash position of €21.7 million. In 2025, THX Pharma raised nearly €8 million.
Focus on Key Development Programs
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The company remains focused on two main programs. TX01, a new formulation aimed at treating Gaucher's disease and Niemann-Pick type C, is expected to have its regulatory filings in 2026, with commercialization planned as early as 2027 by Biocodex and Exeltis in their respective territories. Batten-1, a drug candidate targeting the juvenile form of Batten disease, benefits from a global licensing agreement with Biocodex, which will cover all development costs aiming for commercialization by the end of 2029.
Related
SectorIndustrie Pharmaceutique et Biotechnologie›Biotechnologie
Context
Period
Period: 2025
Key reported figures
Revenue: 813K€
Net income: -3 002 k€
Guidance from the release
L'accord stratégique récemment conclu avec Biocodex,...
THX Pharma renforce sa solidité financière.
Risks mentioned
Pression sur les coûts de développement liée aux essais cliniques.
Incertitude réglementaire sur les projets de commercialisation.
Opportunities identified
Lancement clinique de TX01 et Batten-1 en 2026.
Accord stratégique avec Biocodex.
Visibilité financière sécurisée avec Biocodex.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
